Inflammatory bowel diseases like ulcerative colitis remain among the most difficult chronic conditions to manage — but new science at the intersection of microbiome research and biotechnology may offer hope.

In this episode of The Mind-Gut Conversation, I sit down with Dr. Deanna Gibson, microbiome researcher and cofounder of Melius Microbiomics, to explore how genetically engineered microbial medicines could transform the future of IBD treatment — and what it will take for patients and the medical community to embrace them.

In this conversation, we explore:

· How Dr. Gibson’s research led to the development of BioPersist™ and BioColonize™ for IBD.

· Why new microbiome-targeted therapies are urgently needed — especially for younger patients in whom ulcerative colitis is on the rise.

· What makes BioPersist™ different from traditional probiotics and current IBD treatments.

· How genetically engineered microbial medicines (GEMMs) represent a new generation of gut therapies.

· Early research findings that support BioPersist™ as a promising treatment for ulcerative colitis.

· Challenges in gaining public trust for novel biotech therapies amid growing skepticism.

· Exciting new discoveries in microbiome science — and the future potential for live biotherapeutics beyond IBD.

If you’re curious about the exciting direction where gut health research is headed — and how the microbiome may change the way we treat chronic disease — this episode is for you.

Tune in and join the conversation!

Disclaimer: Dr. Mayer is the Chief Medical Officer of Melius Microbiomics and has been involved in the commercial development of Genetically Engineered Microbial Medicines (GEMMs).